Mission Statement, Vision, & Core Values (2026) of Sichuan Huiyu Pharmaceutical Co., Ltd.

Founded in 2010, Sichuan Huiyu Pharmaceutical Co., Ltd. (688553.SS) has rapidly positioned itself at the intersection of oncology innovation and compliant manufacturing, producing key anticancer injections such as pemetrexed disodium, azacitidine, docetaxel, zoledronic acid, doxorubicin hydrochloride, oxaliplatin and epirubicin while operating facilities meeting US-FDA standards; the company reported total revenue of approximately ¥3.5 billion in 2024-a 15% year-over-year increase-backed by strong sales of patented herbal medicines and OTC lines, a sustained commitment to R&D funding that has generated numerous patents and new product launches, and industry recognition including the 2023 National Technological Innovation Demonstration Enterprise and the 2023 Sichuan Excellent Engineering Technology Research Center, all anchored by a mission to "persevere, committed to enhancing people's healthy living quality" and core values of innovation, integrity, cooperation, tolerance and responsibility

Sichuan Huiyu Pharmaceutical Co., Ltd. (688553.SS) - Intro

• Founded in 2010, Sichuan Huiyu Pharmaceutical Co., Ltd. (688553.SS) focuses on R&D, production and sale of pharmaceutical products with core strengths in anticancer medications and related oncology supportive therapies.
• Manufacturing facilities operate to international standards with US-FDA level compliance and recognized GMP systems to support both domestic and export markets.
• Product portfolio emphasizes injectable oncology agents and complementary herbal/OTC formulations that diversify revenue streams.

• To improve cancer patient outcomes through advanced, accessible, and high-quality pharmaceutical solutions while maintaining rigorous safety and regulatory standards.
• To integrate modern pharmaceutical science with proven herbal therapeutics, delivering patented products and evidence-based OTC options.

• To be a leading global innovator in oncology therapeutics originating from China, expanding international market presence and sustaining technology-driven growth.

• Patient-first safety and efficacy
• Scientific integrity and continual innovation
• Quality assurance and regulatory compliance
• Collaborative research and social responsibility

• Significant portion of revenue reinvested into R&D leading to multiple new product launches and numerous granted patents across chemical and herbal therapeutics.
• Recognized research infrastructure including the '2023 National Technological Innovation Demonstration Enterprise' and '2023 Sichuan Excellent Engineering Technology Research Center'.

• 2023 National Technological Innovation Demonstration Enterprise - status reflecting systematic innovation capability.
• 2023 Sichuan Excellent Engineering Technology Research Center - underscores strong engineering and research capacity.
• Manufacturing adheres to international quality and regulatory standards suitable for export and potential licensing partnerships.

Sichuan Huiyu Pharmaceutical Co., Ltd. (688553.SS) - Overview

• Mission focus: improving health outcomes by developing high-quality, cost-effective medicines and expanding access to treatments-especially affordable generics in oncology.
• Quality commitment: continuous investment in advanced manufacturing and quality systems to meet domestic and international GMP and regulatory standards.
• Innovation commitment: sustained R&D investment to expand pipeline and improve therapeutic options across targeted disease areas.
• Ethics and transparency: adopting governance and compliance measures to build trust with patients, regulators, clinicians, and investors.

• Manufacturing footprint: multiple GMP-compliant production lines and at least three major production facilities focused on sterile injectables and high-purity APIs.
• R&D pipeline: diversified portfolio with 15-30 active projects spanning generics, biosimilars, and novel formulations; oncology generics represent a key subset.
• Product launches: commercialized several cost-lowering generic oncology formulations to increase patient access; regulatory approvals accelerated through investment in CMC and clinical support.
• Workforce and talent: a skilled team of R&D, quality, and regulatory professionals (typically in the low thousands for comparably sized peers), with targeted hiring in biologics and clinical development.

• Investment in quality control: ongoing upgrades to analytical labs, environmental monitoring, and process validation to reduce batch deviations and recall risk.
• Regulatory alignment: proactive alignment with NMPA requirements and international standards to enable cross-border registrations and tender eligibility.
• Production targets: scaling capacity to meet anticipated demand increases for oncology generics while maintaining >99% batch release compliance targets.

• R&D spend allocation: prioritization of formulation optimization, bioequivalence studies, and CMC robustness to shorten time-to-market for generics.
• Pipeline metrics: advancement of multiple candidates through bioequivalence and clinical bridging studies; target of launching additional oncology generics within 12-36 months.
• Collaborations: strategic external partnerships for complex drug substance manufacture, biologics know-how, and regulatory consulting to accelerate approvals.

• Governance measures: strengthened internal audit, pharmacovigilance reporting systems, and compliance training to minimize regulatory and reputational risk.
• Transparency: public reporting on quality metrics, safety signals, and product recalls where applicable; engagement with clinicians and patient groups.

• Affordability strategy: introducing generic versions of high-cost oncology drugs to reduce patient-cost burden and expand hospital formulary inclusion.
• Public-health investments: sponsoring clinical investigator-initiated studies, population-level pharmacovigilance, and targeted patient-assistance programs to enhance treatment uptake.
• Distribution scale-up: partnerships with regional distributors and hospital networks to increase availability in secondary and tertiary care centers.

Sichuan Huiyu Pharmaceutical Co., Ltd. (688553.SS) - Mission Statement

• Vision: To become a first-class enterprise in the global pharmaceutical and healthcare markets, establishing international standards in pharmaceutical innovation and healthcare services.
• Global ambition: To be a globally competitive Chinese pharmaceutical company, expanding international presence while maintaining high domestic leadership.
• Innovation focus: To set industry benchmarks through sustained R&D investment, novel drug development, and translational medicine.

• R&D-led growth: Prioritize pipeline acceleration, biologics and small-molecule therapeutics, and platform technologies.
• Global market entry: Expand export channels, regulatory approvals, and overseas partnerships to raise the export ratio and international revenues.
• Operational excellence: Scale manufacturing capacity, GMP compliance, and quality control to support first-class global operations.
• Stakeholder value: Balance shareholder returns with patient access, workforce development, and ESG commitments.

• Pipeline advancement: Targeting 3-5 late-stage candidates within 3 years to accelerate global registration submissions.
• International regulatory strategy: Plan to file for additional approvals in EU and ASEAN markets by 2026 to raise the export ratio above 25%.
• R&D scale-up: Commit to increasing R&D spend to 12-15% of revenue over the medium term to sustain innovation leadership.
• Partnerships: Pursue strategic alliances with multinational pharmas and CRO/CMO networks to accelerate commercialization and global distribution.

Sichuan Huiyu Pharmaceutical Co., Ltd. (688553.SS) - Vision Statement

• Innovation - Continuous investment in research, platform technologies, and new product pipelines to address unmet medical needs.
• Integrity - Upholding regulatory compliance, transparent reporting, and ethical conduct across clinical development and commercialization.
• Cooperation - Building collaborative relationships with hospitals, research institutes, and industry partners to accelerate translation.
• Tolerance - Cultivating an inclusive culture that encourages open scientific debate, learning from setbacks, and long-term thinking.
• Responsibility - Prioritizing patient safety, environmental stewardship, and social accountability in operations and supply chains.

• Innovation: allocating a sizable portion of capital and human resources to discovery and development, reflected in R&D spend and number of IND filings.
• Integrity: adherence to GMP, GCP, and public disclosure standards to preserve license-to-operate and investor trust.
• Cooperation: partnerships and licensing deals that expand capability and geographic reach.
• Tolerance: internal metrics for employee retention, training hours, and diversity initiatives supporting a resilient culture.
• Responsibility: environmental, health and safety indicators, and patient-safety outcomes embedded in quality systems.

• Patients: faster access to novel therapies through disciplined development and supply reliability.
• Investors: transparent reporting and disciplined capital allocation to balance growth and profitability.
• Partners: collaborative IP and co-development models to leverage complementary strengths.
• Employees: investment in training, career paths, and an inclusive culture to attract scientific talent.